Are antimitochondrial antibodies of prognostic value in primary biliary cirrhosis?

N. Smith,J. Boyer

DOI: https://doi.org/10.1002/hep.1840060433

IF: 17.298

1986-07-01

Hepatology

Abstract:Primary biliary cirrhosis (PBC) is a chronic disorder of unknown etiology characterized by progressive nonsuppurative destruction of the intrahepatic bile ducts, often leading to cholestasis, cirrhosis and hepatic failure. Since the original report by Addison and Gull (1) in 1851 and its modem day description by Ahrens et al. (2), considerable knowledge of the pathologic stages, immunologic disturbances, natural history and prognosis has been acquired. However, our understanding of PBC remains incomplete, particularly with respect to etiology and treatment. Over the past several years, significant data have been accumulated regarding the natural history of PBC and factors that determine its prognosis (3-5). Early published studies of small numbers of patients found the average life expectancy after the onset of symptoms to range from 5 to 8 years (6, 7). In a large, retrospective study, 280 patients were followed, with a mean survival time from the onset of symptoms of 11.9 years (3). This increase in survival is presumably due to a larger patient series and detection of the disease prior to the development of late stage and more classic diagnostic features of PBC. There has also been increased recognition of PBC in patients without symptoms of liver disease (3, 8-1 1). These asymptomatic patients are discovered with liver function test abnormalities or hepatomegaly, and are diagnosed when antimitochondrial antibodies (AMAs) and consistent liver biopsy findings are obtained. The survival curves of these patients are no different than those of an age and sex-matched general population over a median follow-up of 11.4 years, as reported by Beswick et al. (10). Furthermore, the majority (59%) of patients remained asymptomatic. The good prognosis of the asymptomatic PBC patients would at first appear to be due to earlier diagnoses and a longer presymptomatic interval. However, in several studies, the average age of asymptomatic patients at presentation was either similar to or higher than symptomatic PBC patients (3,9-11). A number of other clinical variables in PBC have been correlated with prognosis by several groups (3, 5). Patients do more poorly if they present with advanced age, jaundice, hepatomegaly, splenomegaly, weight loss or ascites, although only the presence of advanced age, jaundice and hepatomegaly were independent discriminators of a poor prognosis when a multivariate analysis was performed (3). Biochemical abnormalities are multiple in PBC, yet elevation of serum bilirubin is the most significant discriminator of a poor prognosis (3, 5, 12). In addition, in one study, a high serum albumin was